The 2026 network meta-analysis of topical acne antibiotics studied general acne-vulgaris trial participants, a pool dominated by adolescents and young adults. It did not study adults with persistent acne as a distinct subgroup. A network meta-analysis combines results from many trials to compare treatments indirectly. Here it compared topical antibiotic monotherapy — one antibiotic applied to skin — against placebo or another topical antibiotic.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What the researchers compared
- Who was actually enrolled
- Who was not studied separately
- What to do for persistent adult acne
What the researchers compared
The reviewers searched MEDLINE, Embase, Cochrane Library, Web of Science, Google Scholar and ClinicalTrials.gov from January 2000 to August 2023, updated October 21, 2025, for randomized trials of topical antibiotic monotherapy. According to the Clinical Drug Investigation review, the eligible comparison was monotherapy versus placebo or another topical antibiotic, described in the Springer Nature Link analysis.
That analysis found inconsistent efficacy and uncertain safety across lesion types, with only mild benefit and no consistent superiority over placebo. The authors said routine monotherapy should be limited amid antibiotic-resistance concerns.
Who was actually enrolled
Participants were people with general acne vulgaris enrolled in standard drug trials. That pool skewed young, as shown in a Cochrane overview of 275 acne trials reporting ages 10 to 59 with average ages 18 to 30, summarized in the ResearchGate Cochrane summary.
This matters for adults with breakouts past age 25. Persistent facial acne affects many adults over 25, including about 12% of women and 3% of men with persistent disease. Trial averages centered near 18 to 30 do not match that older, longer-duration group.
Who was not studied separately
Adults with persistent acne were not analyzed as their own group. Pregnant or nursing people were generally excluded, consistent with acne evidence reviews listing pregnancy or lactation, recent systemic antibiotics or recent oral isotretinoin, and cystic lesions needing systemic therapy as exclusions.
Severe, nodulocystic, conglobate or scarring acne was also not the focus. NICE reserves oral isotretinoin for people over 12 with severe treatment-resistant acne such as nodulocystic disease or acne at risk of permanent scarring, described in the NICE NG198 recommendations.
What to do for persistent adult acne
The 2026 network compared monotherapies only, not the fixed-dose combinations with benzoyl peroxide or retinoids now preferred for persistent adult disease. Much of the underlying trial evidence in prior acne networks was rated moderate to very low quality. For adults with ongoing breakouts, the practical step is to avoid antibiotic-only creams or gels and ask about combination treatment: US 2024 acne guidelines strongly recommend benzoyl peroxide, topical retinoids and/or topical antibiotics in fixed-dose combinations, not antibiotic monotherapy, reported by the American Academy of Dermatology in the Newswise guideline announcement.
- ask about a fixed-dose product combining benzoyl peroxide, a topical retinoid, and/or a topical antibiotic
- do not use a topical antibiotic alone for weeks without a combination partner
- ask about duration, resistance risk, and follow-up for scarring or nodules
You Might Also Like
- The 2026 Review of Topical Antibiotic Monotherapy for Acne: Who Was Studied and Who Was Not for Adults With Persistent Acne
- Limited Topical Spironolactone Evidence in the 2026 Review: Who Was Studied and Who Was Not for Adults With Persistent Acne
- Topical Clascoterone Evidence Revisited in 2026: Who Was Studied and Who Was Not for Adults With Persistent Acne